So, in the tumor microenvironment, the quantity of sIL-6R is smaller than the amount of sgp130 in BPH patients, resulting in the concomitant activation of two signaling pathways mediated by IL-6 (the classic way and trans-signaling). The gene discussed is IL6R; the disease is benign prostatic hyperplasia.